Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026

Fate Therapeutics, Inc. (NASDAQ: FATE) announced that four abstracts from its off-the-shelf CAR T-cell programs will be presented at the ACR Convergence 2026, scheduled for November 6-11 in Orlando, Florida. The presentations will cover various aspects of the company's iPSC-derived CAR T-cell pipeline, including updated clinical data for FT819, a focus group study on patient preferences for CAR T-cell therapy in lupus, and progress on the COMPLETE Trial for FT839, which targets autoimmune diseases.